---
document_datetime: 2023-09-21 19:27:50
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/myalepta-epar-all-authorised-presentations_en.pdf
document_name: myalepta-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.0562071
conversion_datetime: 2025-12-25 05:05:56.853769
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | Invented name   | Strength   | Pharmaceutical Form               | Route of Administration   | Immediate Packaging   | Pack size   |
|------------------|-----------------|------------|-----------------------------------|---------------------------|-----------------------|-------------|
| EU/1/18/1276/001 | Myalepta        | 11.3 mg    | Powder for solution for injection | Subcutaneous use          | vial (glass)          | 1 vial      |
| EU/1/18/1276/002 | Myalepta        | 11.3 mg    | Powder for solution for injection | Subcutaneous use          | vial (glass)          | 30 vials    |
| EU/1/18/1276/003 | Myalepta        | 3 mg       | Powder for solution for injection | Subcutaneous use          | vial (glass)          | 1 vial      |
| EU/1/18/1276/004 | Myalepta        | 3 mg       | Powder for solution for injection | Subcutaneous use          | vial (glass)          | 30 vials    |
| EU/1/18/1276/005 | Myalepta        | 5.8 mg     | Powder for solution for injection | Subcutaneous use          | vial (glass)          | 1 vial      |
| EU/1/18/1276/006 | Myalepta        | 5.8 mg     | Powder for solution for injection | Subcutaneous use          | vial (glass)          | 30 vials    |